RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Quantum Genomics P/S 2024

Quantum Genomics P/S

0.03

Quantum Genomics Dividend yield

Ticker

ALQGC.PA

ISIN

FR0011648971

WKN

A1XAEB

As of May 15, 2024, Quantum Genomics's P/S ratio stood at 0.03, a -99.99% change from the 586.23 P/S ratio recorded in the previous year.

The Quantum Genomics P/S history

Quantum Genomics Aktienanalyse

What does Quantum Genomics do?

Quantum Genomics SA is a French biotechnology company focused on the discovery and development of novel therapies for the treatment of cardiovascular diseases. The company was founded in 2005 in Grenoble, France, where its headquarters are still located. Over 25 employees are currently working on the development of new drugs. The business model of Quantum Genomics SA is based on the research and development of new and innovative solutions for the cardiovascular disease market. The company focuses on a new class of drugs that target the brain to lower blood pressure and treat certain cardiovascular diseases. The goal of these new therapies is to improve the effectiveness of existing treatment methods by directly addressing the causes of the disease. Quantum Genomics SA has established partnerships with renowned research institutes and universities. The collaboration with these institutions aims to accelerate and intensify the research and development of new drugs. Through this collaboration, the company will be able to develop new solutions and therapies to treat cardiovascular diseases at a faster pace. The company is currently working on two main products: Firibastat and the QT-Glutamylcyclotransferase inhibitor. Firibastat is an oral medication developed for the treatment of hypertension. The QT-Glutamylcyclotransferase inhibitor is another medication that is intended to lower blood pressure. These are promising new solutions that can enable Quantum Genomics SA to play a significant role in the cardiovascular disease market. The products of Quantum Genomics SA aim to treat cardiovascular diseases better and more effectively by directly targeting the brain. This aims to reduce the risk of serious complications and side effects that may occur with conventional medications. In recent years, Quantum Genomics SA has received several awards, including the "Innovation Prize" from the French government. These awards demonstrate that the company is on the right track and achieving its goals. Overall, Quantum Genomics SA has a promising business model based on the development of new therapies for the treatment of cardiovascular diseases. With collaborations with renowned research institutes and the development of promising new products, the company is well-positioned to be successful and make significant progress in the growing market of cardiovascular diseases. Quantum Genomics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Quantum Genomics's P/S Ratio

Quantum Genomics's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Quantum Genomics's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Quantum Genomics's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Quantum Genomics’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Quantum Genomics Stock

What is the price-to-earnings ratio of Quantum Genomics?

The price-earnings ratio of Quantum Genomics is currently 0.03.

How has the price-earnings ratio of Quantum Genomics changed compared to last year?

The price-to-earnings ratio of Quantum Genomics has increased by -99.99% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Quantum Genomics high compared to other companies?

Yes, the price-to-earnings ratio of Quantum Genomics is high compared to other companies.

How does an increase in the price-earnings ratio of Quantum Genomics affect the company?

An increase in the price-earnings ratio of Quantum Genomics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Quantum Genomics affect the company?

A decrease in the price-earnings ratio of Quantum Genomics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Quantum Genomics?

Some factors that influence the price-earnings ratio of Quantum Genomics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Quantum Genomics pay?

Over the past 12 months, Quantum Genomics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Quantum Genomics is expected to pay a dividend of 0 EUR.

What is the dividend yield of Quantum Genomics?

The current dividend yield of Quantum Genomics is .

When does Quantum Genomics pay dividends?

Quantum Genomics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Quantum Genomics?

Quantum Genomics paid dividends every year for the past 0 years.

What is the dividend of Quantum Genomics?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Quantum Genomics located?

Quantum Genomics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Quantum Genomics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Quantum Genomics from 5/15/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 5/15/2024.

When did Quantum Genomics pay the last dividend?

The last dividend was paid out on 5/15/2024.

What was the dividend of Quantum Genomics in the year 2023?

In the year 2023, Quantum Genomics distributed 0 EUR as dividends.

In which currency does Quantum Genomics pay out the dividend?

The dividends of Quantum Genomics are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Quantum Genomics

Our stock analysis for Quantum Genomics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Quantum Genomics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.